News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the ...

Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results , with sales up 10.3% year on year to $3.79 billion. Its ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stock has experienced a notable downturn, touching a 52-week low of $666. With a ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Stock analysts at Leerink Partnrs upped their Q1 2025 earnings per share (EPS) estimates for Regeneron Pharmaceuticals in a ...

While Regeneron has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question ...

REGENERON PHARMACEUTICALS ($REGN) posted quarterly earnings results on Tuesday, February 4th. The company reported earnings of $12.07 per share, beating estimates of ...

REGENERON PHARMACEUTICALS ($REGN) is expected to release its quarterly earnings data on Tuesday, February 4th before market open. Analysts are expecting revenue of ...

Leerink Partners upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) from a market perform rating to an ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $71.75 billion, has been navigating a complex landscape of opportunities and challenges in recent months. According to ...

Kingsview Wealth Management LLC raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 16.5% in the fourth quarter, according to the company in its most recent ...